Sign in Subscribe
Cancer research

Roswell Park Cancer Institute Launches Clinical Trial to Study Effectiveness of Selvigaltin in Treating Relapsed/Refractory Multiple Myeloma

Strategic Insights

— 1 min read

The Roswell Park Cancer Institute has announced the launch of an interventional clinical trial to study the effectiveness of GB1211 (selvigaltin), an oral galectin-3 inhibitor, in combination with standard of care treatment in patients with relapsed or refractory multiple myeloma. The trial, which has an enrollment of 21 participants from the USA, is still not open for recruiting and is led by principal investigator Hamza Hassan. The trial aims to evaluate the safety, tolerability, and efficacy of selvigaltin in combination with standard of care treatment, which includes daratumumab-hyaluronidase, carfilzomib, and dexamethasone.

Key Takeaways:

  • The trial is a Phase 1 study aimed at assessing the side effects and best dose of selvigaltin when administered with standard of care treatment for multiple myeloma patients.
  • Selvigaltin is an oral galectin-3 inhibitor that blocks the activity of galectin-3, a protein involved in cellular processes such as inflammation and tissue scarring, which is linked to poorer cancer outcomes.
  • The combination therapy includes daratumumab-hyaluronidase, carfilzomib, and dexamethasone, which work by blocking CD38, inhibiting cancer cell growth, and reducing inflammation and immune response, respectively.
  • The trial aims to establish the safety, tolerability, and efficacy of selvigaltin in combination with standard of care treatment for patients with relapsed or refractory multiple myeloma.
  • Principal investigator Hamza Hassan is leading the trial, which has a sample size of 21 participants from the USA.
  • The trial's purpose is to explore the potential benefits of combining shelvigaltin with standard of care treatment in patients with relapsed or refractory multiple myeloma.

Statistics:

  • The trial is a Phase 1 study, which is the first stage of human clinical trials, designed to assess safety and dosing of new drugs.
  • The study aims to enroll 21 participants from the USA.
  • The combination therapy includes four different medications: daratumumab-hyaluronidase, carfilzomib, dexamethasone, and selvigaltin.
  • Galectin-3 is a protein involved in various cellular processes, including inflammation and tissue scarring, which is associated with worse outcomes in several forms of cancer.

Sources:

  • ClinicalTrials.gov
  • https://clinicaltrials.gov/study/NCT07082270

Read more